Effective multimodal management of a giant adrenocortical carcinoma

Acta Chir Belg. 2023 Aug;123(4):444-447. doi: 10.1080/00015458.2022.2040109. Epub 2022 Feb 17.

Abstract

Background: Adrenocortical carcinoma is a rare and aggressive tumour. The only curative treatment is surgery with negative margins. In most series, the average lesion size ranges from 5.5 to 15 cm.

Methods: We report the case of a 27-year-old female with hyperandrogenism and Cushing syndrome due to a right adrenocortical carcinoma of 19.7 cm.

Results: The tumour abutting on liver and vena cava and the presence two nodules in liver required extensive surgery including a right posterior sectionectomy and an en bloc resection of the adrenal mass together with the right kidney and the gallbladder. The vena cava was also resected with a reconstruction using a pericardial patch since it was invaded on its border. Pathological examination confirmed an adrenocortical carcinoma, with tumour invasion of vessels, tumour capsule, vena cava and two metastases in the liver (pT4N0M1). All margins were negative. Three months after surgery, two lung nodules, cardio-phrenic and internal mammary adenomegalies were noticed on a PET/CT scan, justifying the initiation of chemotherapy, alongside with mitotane. After a 10-month follow-up, CT scan was stable excepted for a lung nodule growing from 4 to 7 mm. Targeted stereotaxic radiotherapy was then administered. Twenty-two months after surgery, the patient has improved considerably and all signs of hyperandrogenism and Cushing syndrome have resolved.

Conclusion: This case of adrenocortical carcinoma illustrates one of the largest tumours among those reported. It demonstrates the feasibility and effectiveness of a multimodal approach in its treatment even if it is giant and at high risk.

Keywords: Adrenocortical carcinoma; Cushing’s syndrome; hyperandrogenism.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Neoplasms* / therapy
  • Adrenocortical Carcinoma* / therapy
  • Adult
  • Combined Modality Therapy
  • Cushing Syndrome
  • Female
  • Humans
  • Hyperandrogenism